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Pairwise Sequential Randomization and Its Properties
SUMMARY: In comparative studies, such as in causal inference and clinical
trials, balancing important covariates is often one of the most important
concerns for both efficient and credible comparison. However, chance im-
balance still exists in many randomized experiments. This phenomenon of
covariate imbalance becomes much more serious as the number of covari-
ates p increases. To address this issue, we introduce a new randomization
procedure, called pairwise sequential randomization (PSR). The proposed
method allocates the units sequentially and adaptively, using information
on the current level of imbalance and the incoming unit’s covariate. With a
large number of covariates or a large number of units, the proposed method
shows substantial advantages over the traditional methods in terms of the
covariate balance, estimation accuracy, and computational time, making it
an ideal technique in the era of big data. The proposed method attains the
optimal covariate balance, in the sense that the estimated treatment effect
under the proposed method attains its minimum variance asymptotically.
Also the proposed method is widely applicable in both causal inference and
clinical trials. Numerical studies and real data analysis provide further
evidence of the advantages of the proposed method.
KEYWORDS: Asymptotic variance; Big Data; Causal Inference; Clinical
trial; Experiment design; Treatment effect.
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1 Introduction
Randomization is the foundation for the treatment effect evaluation. However, tradi-
tional randomization methods often generate unsatisfactory configurations with unbal-
anced prognostic covariates; this issue has been extensively discussed ever since Fisher
(1926) noted: “Most of experimenters on carrying out a random assignment of plots
will be shocked to find out how far from equally the plots distribute themselves.” The ad-
vantages of balanced covariates are at least threefold (Hu et al., 2014). First, covariate
balance improves the efficiency of estimation for the treatment effect. Second, it in-
creases the interpretability of the estimated treatment effect by making the units in the
treatment groups more comparable, thereby enhancing the credibility of the analysis.
Third, it makes the analysis more robust against model misspecification. Consequently,
covariate imbalance can significantly undermine the validity of subsequent analysis. In
the absence of covariate balance, various problems must be addressed before a valid
conclusion can be drawn.
In causal inference and clinical studies, if a significant imbalance exists, any in-
ferences regarding the treatment effect will be inaccurate, and any claims about the
treatment effect will need to rely on unverifiable assumptions (Lock, 2011). Researchers
must assess the balance in the covariate distribution before estimating the causal ef-
fect. Although some ex-post adjustments, such as regression (Freedman, 2008) and
subsample selection using matching or trimming based on propensity scores (Imbens
and Rubin, 2015), can cope with such an imbalance, they are much less efficient than
achieving an ex-ante balance from the start (Bruhn and McKenzie, 2008). In addition,
these adjustments often rely on at least a nearly correct model, which can be diffi-
cult to test (Cochran, 1965; Cochran and Rubin, 1973). Rubin (2008) explained why
the greatest possible efforts should be made during the design phase of an experiment
rather than during the analysis stage, at which point the researcher has the potential
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to bias the results (Lock, 2011; Imbens and Rubin, 2015).
More recently, covariate balance has attracted growing interest in the field of
crowdsourced-internet experimentation (Horton et al., 2011; Chandler and Kapelner,
2013; Kapelner and Krieger, 2014). Researchers increasingly recruit workers from on-
line labor markets into their experiments, such as by asking them to label tumor cells
in images. Because of the nature of the recruiting process, a large number of workers
with many covariates (e.g., 2500 workers in Chandler and Kapelner (2013)), typically
are enrolled in such studies, which consequently pose challenges for traditional ran-
domization methods.
Furthermore, the phenomenon of covariate imbalance is exacerbated as the number
of covariates p and the sample size n increase, which is nearly ubiquitous in the era of
big data. For example, suppose that the probability of one particular covariate being
unbalanced is 5%. For a study with 10 independent covariates, the chance of at least
one covariate exhibiting imbalance is 1 − (1 − 5%)10 = 40%. Meanwhile, some may
argue that imbalance tends to be milder as the sample size increases. However, as the
sample size increases, even though the difference in covariate means between groups
becomes smaller, however, at the same rate, confidence intervals and hypothesis testing
are becoming more sensitive to small differences in outcome variables which can be
affected by the small imbalance in covariates (Morgan and Rubin, 2012).
In the framework of causal inference, Morgan and Rubin (2012) have proposed
rerandomization (RR). They propose to repeatedly randomize the units into treat-
ment groups using complete randomization (CR), until certain the balance criterion is
satisfied, e.g., M < a, where M is the Mahalanobis distance between the sample means
across different treatment groups and a > 0 is a threshold.
M = (x¯1 − x¯2)T [cov(x¯1 − x¯2)]−1(x¯1 − x¯2)
∝ (x¯1 − x¯2)T cov(x)−1(x¯1 − x¯2),
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where x¯1 ∈ Rp and x¯2 ∈ Rp are the sample means for two treatment groups, cov(x) ∈
Rp×p is the covariance matrix of the covariate. They has also assumed fixed equal num-
bers of units in two treatment groups and demonstrated various desirable properties
under rerandomization.
Although rerandomization works well in the case of a few covariates, it is incapable
of scaling up to address massive amounts of data. For example, as the number of
covariates increases, the probability of acceptance, pa = P (M < a), of each complete
randomization decreases drastically, causing the rerandomization procedure to remain
in loop for a long time. To compromise the computational burden, one can increase a,
which unavoidably leads poorer covariate imbalance.
In clinical trials, to balance important covariates, most existing methods such as
stratified permuted block design, minimization methods (Taves, 1974; Pocock and Si-
mon, 1975; Hu and Hu, 2012) and CA-BCD (Antognini and Zagoraiou, 2011) are only
for discrete covariates. Discretizing continuous covariates is often less efficient and
changes the nature of the covariates. A variety of methods for balancing continuous
covariates have been proposed in the literature: the methods based on ranks (Ciolino
et al., 2011; Hoehler, 1987; Stigsby and Taves, 2010); based on p-value (Frane, 1998);
based on Kullback-Leibler divergence (KLD); based on empirical cumulative distribu-
tion (Lin and Su, 2012); based on kernel density (Ma and Hu, 2013), etc. However,
the performance of those procedures was usually evaluated by simulation studies, their
theoretical properties are not well investigated in literature. Also these methods are
usually applicable for only a few covariates.
In this article, we propose a new approach — pairwise sequential randomization
(PSR) — to generate a more balanced treatment allocation and thus to improve the
subsequent analysis for both causal inference and clinical trails settings. Unlike reran-
domization or complete randomization, in which all units are allocated independently,
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we allocate units adaptively and sequentially by assigning one randomly chosen pair of
units at a time. For each pair of units, using their covariate information and the exist-
ing level of imbalance of the previously allocated units, we adjust the probability with
which the pair is allocated to treatment groups to avoid incidental covariate imbalance.
In this way, we are able to produce a much more balanced allocation of units. The
properties of the PSR procedure are illustrated both theoretically and numerically.
The advantages of the proposed method are: (i) For cases with a large number of
covariates or a large number of units, the proposed method exhibits superior perfor-
mance, with more balanced randomization and less computational time; (ii) The PSR
procedure attains the optimal covariate balance, in the sense that the estimated treat-
ment effect under the proposed method attains its minimum variance asymptotically;
and (iii) The proposed procedure is designed for directly randomizing units with both
continuous and discrete covariates. Therefore the PSR procedure is widely applicable
for balancing many important covariates in comparative studies.
This article is organized as follows. We introduce the proposed method and inves-
tigate its theoretical properties in Section 2. We demonstrate its advantages in the
treatment effect estimation and present theoretical properties in Section 3. Numer-
ical studies to verify the finite sample properties of the proposed method are shown
in Section 4. We further present an real data example to demonstrate the superior
performance of our method in Section 5. Finally, we conclude with a discussion in
Section 6 and relegate the outlining of proofs to Section 7.
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2 Pairwise Sequential Randomization
2.1 Proposed Method and Its Properties
Suppose that n units (patients) are to be assigned to two treatment groups. Let Ti
be the assignment of the i-th unit, i.e., Ti = 1 for treatment 1 and Ti = 0 for treat-
ment 2. Consider p continuous covariates for each unit. Let xi = (xi1, ..., xip)
T ∈ Rp
represent the covariates of the i-th unit. Suppose all units are available for assign-
ment at the beginning of the randomization. We choose the Mahalanobis distance
as the covariate imbalance measure, M(n) = (x¯1 − x¯2)T cov(x¯1 − x¯2)−1(x¯1 − x¯2) ∝
(x¯1 − x¯2)T cov(x)−1(x¯1 − x¯2). This Mahalanobis distance functions as a measure of
the covariate balance throughout this article. A smaller value of M(n) indicates a bet-
ter covariate balance. To assign units to treatment groups, we propose the following
procedure, pairwise sequential randomization (PSR).
(1) Arrange all n units randomly into a sequence x1, ...,xn.
(2) Assign the first two units with T1 = 1 and T2 = 0.
(3) Suppose that 2i units have been assigned to treatment groups, for the (2i+ 1)-th
and (2i+ 2)-th units:
(3a) If the (2i+ 1)-th unit is assigned to treatment 1 and the (2i+ 2)-th unit to
treatment 2, then we can calculate the “potential” Mahalanobis distance,
M1(2i+ 2), between the updated treatment groups with 2i+ 2 units.
(3b) Similarly, if the (2i+1)-th unit is assigned to treatment 2 and the (2i+2)-th
unit to treatment 1, then we can calculate the other “potential” Mahalanobis
distance, M2(2i+ 2).
(4) Assign the (2i+ 1)-th unit to treatment groups according to the following prob-
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abilities:
P (T2i+1 = 1|x2i, ...,x1, T2i, ..., T1) =

q if M1(2i+ 2) < M2(2i+ 2),
1− q if M1(2i+ 2) > M2(2i+ 2),
0.5 if M1(2i+ 2) = M2(2i+ 2),
where 0.5 < q < 1, and assign T2i+2 = 1−T2i+1 to maintain the equal proportions.
(5) Repeat the last two steps until all units are assigned. If n is odd, assign the last
unit to two treatments with equal probabilities.
There are several advantages for adopting Mahalanobis distance as the imbalance
measure. First, it is an affinely invariant imbalance measure, which is appealing espe-
cially for multivariate data. It is an overall imbalance measure which standardizes and
aggregates each covariate imbalance information. A low Mahalanobis distance guar-
antees low imbalance levels in all covariates. Note that when the covariance matrix is
identity matrix, the Mahalanobis distance essentially becomes the L2 norm of the im-
balance vector, which is a traditional measure of covariate imbalance in clinical trials.
In addition, using Mahalanobis distance as imbalance measure, various desirable sta-
tistical properties can be obtained, such as the reduction in variance of the estimated
treatment effect and optimal asymptotic variance for treatment effect estimation. In
practice, the covariance matrix is replaced with the sample covariance matrix.
The value of q is set to 0.75 throughout this article. Different values of q will not
affect the theoretical results presented in this article. For a further discussion of q,
please see Hu and Hu (2012). Note that the sequence in which the units are allocated
is not unique. Rather, there are n! different possible sequences, but their performances
are similar, especially when n is large.
We now study the asymptotic properties of the Mahalanobis distance, M(n), ob-
tained using the proposed method.
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Theorem 2.1. Under the pairwise sequential randomization (PSR), suppose that the
covariate xi, i = 1, ..., n, is independent and identically distributed as a multivariate
normal distribution with zero mean; then we have M(n) = Op(n
−1).
Note that the Mahalanobis distance that is obtained through the complete ran-
domization, MCR(n), has a stationary distribution of a Chi-square distribution with p
degrees of freedom (regardless of n), i.e., MCR(n) ∼ χ2df=p. Therefore, the Mahalanobis
distance obtained through rerandomization, MRR(n), has a conditional Chi-square dis-
tribution, i.e., MRR(n) ∼ χ2df=p|χ2df=p < a. Hence, as the sample size n increases, the
proposed method reveals a greater advantage over both rerandomization and complete
randomization, because M(n) converges to 0 at the rate of 1/n. That is, the more
units included, the better the covariate balance becomes.
Moreover, as the number of covariates p increases, the distribution of MCR(n) be-
comes flatter, which implies poorer allocation in terms of covariate balance. As a conse-
quence, rerandomization has a lower probability of acceptance, pa = P (MCR(n) < a).
Therefore, the advantage of the proposed method also becomes more significant as
p increases, because the M(n) obtained using the proposed method converges to 0
regardless of the magnitude of p.
In Figure 1, we conduct a simple simulation by plotting the sequences of Maha-
lanobis distance as more units are assigned using the proposed method. As we can
see, the trajectories converges to zero approximately at the speed of 1/n. Extensive
simulation studies can be found in Section 4.
2.2 Clinical Trial Settings
The proposed algorithm can be easily adopted in clinical trial studies where patients are
sequentially enrolled and the treatment is conducted after the individual enrollment.
Since the units come in a natural order, we do not need Step 1 anymore. In order to
7
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Figure 1: Convergence of M(n) using the proposed method. Solid curves are fitted
trends M = c/n with c > 0.
have a valid covariance matrix estimate, we also need to increase the burn in number in
Step 2 to be larger than p. For example, we can implement the first m pairs (2m > p)
by simple randomization (in each pair, the assignment is (1, 0) or (0, 1) with half
probability). For the (i+ 1)th pair (here i > m), 2i units have already been enrolled in
study. In Step 3, one calculate calculate the potential Mahalanobis distance, we only
need to use the sample covariance matrix of 2i units, Σ̂2i. Other steps are the same.
In literature, continuous covariates are usually discretized in order to be included
in the above balancing procedures. However, breakdown of a continuous covariate into
subcategories means increased effort and loss of information as pointed in Scott et al.
(2002). Ciolino et al. (2011) further pointed out that: “Lack of publicity for practical
methods for continuous covariate balancing and lack of knowledge on the cost of failing
to balance continuous covariates results in a common phenomenon, whereby continuous
covariates are excluded from the randomization plan in clinical trials.” It is important
to note that the proposed method is designed for directly randomizing units with
continuous covariates. Also the PSR procedure works well for large p and n, while the
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other methods only work for small p.
Through simulation studies (Section 4), we can show that the above scenarios yield
similar results in terms of covariate balance especially when sample size is large.
3 Treatment Effect Estimation
3.1 Framework
After allocating the units to treatment groups, we are interested in estimating the
treatment effect from the outcome variable yi obtained under the treatment Ti for
i = 1, ..., n. A natural choice is
τˆ =
∑n
i=1 Tiyi∑n
i=1 Ti
−
∑n
i=1(1− Ti)yi∑n
i=1(1− Ti)
, (1)
which is simply the difference in the sample means of yi for the different groups. One
problem with τˆ is that if there is an imbalance in the covariates, it will affect the
accuracy of τˆ . For example, if we estimate the effect of a drug when the treatment 1
group contains mostly males and the treatment 2 group contains mostly females, then
the estimated treatment effect τˆ will not be able to exclude the effect of gender.
To adjust for such an imbalance, we can use linear regression to estimate the treat-
ment effect. That is, conditional on the treatment assignment Ti, each outcome variable
is assumed to follow the model below:
yi = µ1Ti + µ2(1− Ti) + β1xi1 + ...+ βpxip + i, (2)
where µ1 and µ2 are the main effects of treatments 1 and 2, respectively, and µ1−µ2 = τ
is the treatment effect. Furthermore, βj represents the covariate effect, and i is an
independent and identically distributed random error with zero mean and constant
variance σ2 , and is independent of xi = (xi1, ..., xip)
T . All covariates xi, i = 1, ..., n,
are independent and identically distributed.
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Let us define
Y =

y1
y2
...
yn

,X =

xT1
xT2
...
xTn

=

x11 · · · x1p
x21 · · · x2p
...
. . .
...
xn1 · · · xnp

,T =

T1
T2
...
Tn

, T˜ =

T1 1− T1
T2 1− T2
...
...
Tn 1− Tn

,
X˜ = [T˜ ;X], β = (β1, ..., βp)
T , and β∗ = (µ1, µ2, β1, ..., βp)T . Then, we can obtain the
ordinary least squares estimate of β∗:
βˆ∗ = (X˜TX˜)−1X˜TY .
Let us consider L = (1,−1, 0, ..., 0)T , a (p+ 2)-dimensional vector. We define
τ˜ = LT βˆ∗,
which is another estimate of the treatment effect that is adjusted for the imbalance in
the covariates. Note that if X˜ does not include any covariates, i.e., X˜ = T˜ , then the
regression model is yi = µ1Ti +µ2(1−Ti) + i, and τ˜ becomes τˆ in Equation (1), which
is the estimated treatment effect without adjusting for the imbalance in the covariates.
In the next section, we study the properties of τˆ and τ˜ under our proposed method
(i.e., τˆPSR and τ˜PSR) and under complete other randomization methods such as CR and
RR.
3.2 Theoretical Properties
Under complete randomization and rerandomization, τˆCR and τˆRR are unbiased. We
can similarly show the consistency and asymptotic normality of τˆPSR and τ˜PSR for the
proposed method. Before introducing our key properties, we first show the following
properties:
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Theorem 3.1. Under the pairwise sequential randomization (PSR), suppose that the
covariate xi, i = 1, ..., n, is independent and identically distributed as a multivariate
normal distribution with zero mean; then we have
cov[x¯1 − x¯2|X,PSR] = uncov[x¯1 − x¯2|X,CR],
where un = E[M(n)/p|X,PSR] and un = O(n−1).
In randomized experiments, the emphasis typically is placed on the percent reduc-
tion in variance (PRIV) defined by Morgan and Rubin (2012). This quantity represents
the percentage by which the randomization method reduces the variance of the differ-
ences in the means calculated for the different treatment groups. A higher value of the
PRIV indicates that the means are closer to each other. Consider the PRIV for the
j-th covariate,
100
(Var[x¯j,1 − x¯j,2|X,CR]− Var[x¯j,1 − x¯j,2|X,PSR]
Var[x¯j,1 − x¯j,2|X,CR]
)
,
where x¯j,1 and x¯j,2 are the j-th elements of x¯1 and x¯2. According to Theorem 3.1, the
PRIV of each covariate is 100(1 − un)% under the proposed method. Recall that the
PRIV of rerandomization for each covariate is 100(1−va)% where va > 0 is a function of
a. In contrast, for the proposed method, PRIVPSR → 100% as n→∞. which implies
that, as the sample size increases, the covariate imbalance reaches the minimum level.
This is particularly useful when the covariates and outcome are correlated, because in
this case, the proposed method will in turn improve the precision of the estimation of
the treatment effect, as detailed in the following theorem.
Theorem 3.2. Under the pairwise sequential randomization (PSR), suppose that the
outcome variable yi and the covariate xi are normally distributed and that the treat-
ment effect is additive; then, the percent reduction in variance (PRIV) of τˆPSR is
100(1 − un)R2, where R2 is the squared multiple correlation between yi and xi within
the treatment groups, and un = O(n
−1).
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Figure 2: The percent reductions in variance of the estimated treatment effect under
the proposed method, τˆPSR, and under rerandomization, τˆRR, for various sample sizes
and numbers of covariates. Panel (a): proposed method. Panel (b): rerandomization.
Recall that the PRIV of τˆRR is 100(1− va)R2 (Morgan and Rubin, 2012), which is
a constant and does not depend on the sample size. In contrast, the PRIV of τˆPSR is
100(1 − un)R2 and converges to 100R2 as the sample size n → ∞. In fact, the PRIV
of τˆPSR is simply the PRIV of the covariates scaled by R
2. We further plot the PRIVs
of τˆPSR and of τˆRR (with a fixed acceptance probability of pa = 0.05) in Figure 2. Note
that we let R2 = 1 in both figures only for illustrative purposes (as in Morgan and
Rubin (2012)). It is evident that as n increases, at each value of p, the PRIV of τˆPSR
increases to 100%. However, the PRIV of τˆRR at a given p does not vary with different
n. The advantage of the proposed method over rerandomization is clear, especially for
large n and large p.
Meanwhile, the percent reduction in variance due to the adjustment via linear
regression in complete randomization is 100[(1 + MCR(n)/n)R
2 − MCR(n)/n] (Cox,
1982), which converges to 100R2 as n→∞. Therefore, we conclude that the proposed
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method can reduce the asymptotic variance to the minimum level.
In addition, if we further assume that the outcome variable yi truly follows a linear
regression model, we can show that τˆPSR achieves the optimal precision even without
adjusting for the imbalance in the covariates using linear regression. That is,
Theorem 3.3 (Optimal precision). Suppose that the outcome variable yi follows the
linear regression model in Equation (2) and that we estimate the treatment effect under
the proposed method and under complete randomization; then, we have
√
n
(
τˆPSR − (µ1 − µ2)
) D→ N(0, V1),
√
n
(
τ˜PSR − (µ1 − µ2)
) D→ N(0, V2),
√
n
(
τ˜CR − (µ1 − µ2)
) D→ N(0, V3),
√
n
(
τˆCR − (µ1 − µ2)
) D→ N(0, V4),
where 4σ2 = V1 = V2 = V3 < V4.
This theorem implies that under the proposed method, the precision of the esti-
mated treatment effect obtained using a simple sample mean difference, τˆPSR, is the
same as the precision of the estimate obtained through a linear regression which adjusts
for the covariate imbalance, τ˜PSR. This suggests that the regression adjustment would
not be necessary under the proposed method. In other words, the proposed method can
balance the covariates so well that, asymptotically, the simple sample mean difference
τˆPSR is just as good as the linear-regression-adjusted estimate τ˜PSR.
Furthermore, the theorem also implies that the precision of τˆPSR is the same as
the precision of the estimated treatment effect obtained from a linear regression under
complete randomization, τ˜CR, which is considered optimal. Therefore, we conclude
that the τˆPSR attains optimal precision. Although τ˜CR and τˆPSR have the same preci-
sion, it is worth noting that to calculate τ˜CR, it is necessary to estimate all regression
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coefficients β∗, whereas τˆPSR is simply the sample mean difference and does not require
the estimation of any additional coefficients.
Similarly, we present the properties of τˆRR and τ˜RR for comparison. Note that
all properties are derived under the proposed framework which is different from the
framework in Morgan and Rubin (2012).
Corollary 3.4. Under the same assumptions in Theorem 3.3, suppose that we estimate
the treatment effect under the rerandomization; then, we have
√
n
(
τ˜RR − (µ1 − µ2)
) D→ N(0, V5),
√
n
(
τˆRR − (µ1 − µ2)
) D→ N(0, V6),
where 4σ2 = V1 = V2 = V3 = V5 < V6 < V4.
From the theorem above, we conclude that rerandomization cannot achieve the
optimal precision in contrast to the proposed method. It cannot completely remove
the covariate imbalance either. In Table 1, we summarize the relationships of the
asymptotic variances of the different estimates presented by this article.
3.3 Computational Advantage
The previous section clearly demonstrates the advantages of the proposed method. A
natural question is whether we can also let va → 0 in the rerandomization to improve
its performance to match that of the proposed method (because rerandomization al-
lows researchers to increase the power of the analysis at the expense of computational
time (Morgan and Rubin, 2012)). However, this option is extremely computationally
expensive in many cases, as illustrated below.
Theorem 3.5. For rerandomization, to achieve the same level of covariate balance of
the pairwise sequential randomization (PSR) (i.e., the average Mahalanobis distance
14
Randomized Randomization Working model for estimating µ1 − µ2
Covariates Method lm(Y ∼ T˜ ) lm(Y ∼ T˜ +X)
X
CR Asym. Var. > Asym. Var.
∨ ‖
RR Asym. Var. Asym. Var.
∨ ‖
Proposed Asym. Var. = Asym. Var.
Table 1: Demonstration of the relationship of asymptotic variances of different esti-
mates. All results are derived under the proposed framework.
under the PSR), the acceptance probability pa of rerandomization is χ
2
df=p(a
∗), where
χ2df=p(·) is the cumulative distribution function of a Chi-square distribution with p de-
grees of freedom, and a∗ is the root of γ(p/2, a∗/2)Dp2 = 2γ(p/2 + 1, a∗/2)n where
D > 0 is a constant and γ(w, t) =
∫ t
0
xw−1 exp{−x}dx is the incomplete gamma func-
tion.
We report the acceptance probabilities for several scenarios as quantitative values
in Table 2. As we can see, for a small sample size and low-dimensional covariates,
the acceptance probability are reasonable. However, as either p and n increase, the
acceptance probability approaches 0 very fast.
Suppose that the time to allocate one additional unit by the proposed method is
C(p) and that the time to allocate one additional unit by complete randomization is
R > 0. Note that complete randomization is not covariate-adaptive, therefore R does
not depend on p. Suppose that the time to evaluate the Mahalanobis distance is E(p).
Then, we have the following corollary.
Corollary 3.6. To achieve the same level of covariate balance, the ratio of the average
15
n p = 2 p = 5 p = 10 p = 20 p = 30
1000 0.019360138 5.889118e-04 1.366763e-05 2.041414e-07 2.886993e-08
2000 0.009504544 1.058795e-04 4.742458e-07 3.091250e-10 2.424319e-12
3000 0.006528596 3.886533e-05 6.451756e-08 6.184287e-12 7.804135e-15
Table 2: Acceptance probabilities of rerandomization to match the covariate balance
produced by the proposed method for different levels of n and p.
computational time of the proposed method to the average computational time of the
rerandomization method is proportional to χ2df=p(a
∗)C(p)/[E(p)R].
Because of the unknown properties of C(p) and E(p), we are unable to demonstrate
the ratio of computational times as we did in Table 2 for acceptance probability. How-
ever, we have conducted extensive simulation studies in the next section to demonstrate
the computational advantages of the proposed method.
4 Numerical Studies
In this section, we perform simulation studies to verify the theoretical results and
demonstrate the advantages of the proposed method.
4.1 Convergence Rate
First, we perform a simple experiment to verify the rate of convergence stated in The-
orem 2.1. We simulate the unit’s covariate x according to multivariate normal distri-
bution x ∼ MN(0, I). Using different numbers of covariates p, we simulate sequences
of units, assign them to treatment groups and record the corresponding sequences of
Mahalanobis distances. We repeat the procedure for 5000 times and plot the average
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Figure 3: Verification of the rate of convergence of M(n) using the proposed method.
Mahalanobis distance against the reciprocal of the sample size (1/n) in Figure 3. It
is clear that the expected Mahalanobis distance converges to 0 at the rate of 1/n, as
evidenced by the straight lines.
4.2 Pairwise sequential randomization under Different Set-
tings
We also demonstrate the performance of the PSR under two different scenarios: (1)
all units are available for assignment before the randomization starts, such as causal
inference studies, (2) units come to the study sequentially and are assigned to treatment
sequentially, such as clinical trial studies. In both cases, we can adopt the proposed
method, the only difference is the number of burn in and the calculation of the sample
covariance matrix as explained in Section 2.2.
We simulate the unit’s covariate x according to multivariate normal distribution
x ∼ MN(0, I). Using different ps and ns, we simulate these units, assign them to
treatment groups and record the final Mahalanobis distances. We plot the distributions
of the Mahalanobis distance in Figure 4. As the figure shows, the distributions of the
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Figure 4: Comparison of the distributions of the Mahalanobis distances obtained via
the proposed method, M(n), under three scenarios. Red curves are for true covariance
is known. Blue curves are for causal inference. Green curves are for clinical trial.
Mahalanobis distance under these two scenarios are almost identical, especially when
the sample sizes are large. This is because as more and more units are assigned, the
sample covariance matrix converges and the behaviors of Mahalanobis distance are the
same for these two scenarios. This simulation study verifies the applicability of the
proposed method in both two scenarios, i.e., causal inference and clinical trial studies.
4.3 Covariate Balance and Computational Advantage
In this section, we compare the proposed method with other methods, especially reran-
domization, in terms of covariate balance and computational feasibility.
We first compare the proposed method with rerandomization (with pa = 0.05) by
simulating the covariates with x ∼ MN(0, I); the results are presented in Figure 5.
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Figure 5: Comparison of the distributions of the Mahalanobis distances obtained via
the proposed method, M(n), and rerandomization, MRR(n), for different sample sizes
n and different numbers of covariates p.
For different ns and ps, we plot the histograms of M(n) of the proposed method and
MRR(n) of rerandomization. As the figure shows, as n increases, the distribution of
MRR(n) remains unchanged, whereas the distribution of M(n) rapidly converges to 0.
Moreover, as p increases, the distributions obtained through rerandomization and the
proposed method become wider, but the inflation of distribution is much less severe for
the proposed method (i.e., the overlap between the two distributions becomes smaller
as p increases).
Next, we compare the proposed method with rerandomization in terms of compu-
tational times. Note that the proposed method only requires one iteration, whereas
rerandomization requires multiple iterations of complete randomization to achieve an
acceptable balance level. Therefore, we compared the number of iterations required
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Figure 6: Comparison of the numbers of iterations, the computational times, and the
ratios of computational times for rerandomization and the proposed method. Panel
(a): numbers of iterations of rerandomization required to achieve the same performance
as the proposed method. Panel (b): the corresponding computational times used in
Panel (a). Panel (c): the ratios of computational times shown in Panel (b).
for rerandomization to achieve the same performance (same Mahalanobis distance) as
the proposed method. In addition, we also compared the corresponding computational
times. The results are shown in Figure 6. As seen in Figures 6a and 6b, when n and p
are small, the computational advantage of the proposed method is not obvious. As n
and p increase, however, the proposed method gradually shows a significant advantage
over rerandomization, because more iterations and more time are required for reran-
domization in order to achieve the same level of performance as the proposed method.
As p continues to increase, rerandomization will eventually become very computation-
ally expensive. In other words, it is nearly impossible for rerandomization to achieve
the same performance as the proposed method. Note that the computational time of
the proposed method grows only linearly with n and remains the same for different ps,
whereas the computational time of rerandomization grows exponentially as either n or
p increases.
20
4.4 Treatment Effect Estimation
Finally, we compare the proposed method with other randomization methods in terms
of estimating the treatment effect. We simulate ten continuous covariates xi = (xi1, ..., xi10)
T
according to xi ∼ MN(0, I10×10) with sample size of 5000. We applied the proposed
method, rerandomization and complete randomization to these simulated units and
obtained the simulated treatment assignments Ti. We further simulate the outcome
variable according to yi = µ1Ti + µ2(1 − Ti) +
∑10
j=1 βjxij + i, where µ1 = 0, µ2 = 1,
βj = 1 for j = 1, ..., 10 and i ∼ N(0, 22).
Using the simulated data, we estimate the treatment effect using four different
working models and obtain the standard error for each method under different ran-
domization methods.
W1: yi = µ1Ti + µ2(1− Ti) + i
W2: yi = µ1Ti + µ2(1− Ti) +
∑3
j=1 βjxij + i
W3: yi = µ1Ti + µ2(1− Ti) +
∑10
j=4 βjxij + i
W4: yi = µ1Ti + µ2(1− Ti) +
∑10
j=1 βjxij + i
Note that W1 is equivalent to the sample mean difference τˆ . The results are presented
in Table 3, which is consistent with Table 1. As we can see, proposed method obtain
the smallest standard errors among all methods. Rerandomization performs well, but
its standard errors are significantly larger than these of the proposed method. Finally,
not surprisingly, complete randomization has the largest standard errors. As we include
more covariate into the working model, the standard error gradually decreases. This is
because the covariate imbalance is partially adjusted by the linear regression. When all
covariates are included in the working model (i.e., W4), the standard errors becomes
the smallest. Note that the W4 under all randomization methods are almost the
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Randomization method
Working model for estimating µ1 − µ2
W1 W2 W3 W4
CR 6.604616 5.622748 4.006424 1.970360
RR 4.036759 3.544364 2.769106 1.987251
Proposed 2.051219 2.031727 2.003411 1.985727
Table 3: Comparison of standard errors of estimated treatment effect for working
model W1, W2, W3, and W4 under different randomization methods. This table is a
verification of Table 1.
same. This is because covariate imbalance from the randomization methods have been
completely adjusted, therefore, the standard error reaches its minimum.
5 Real Data Example
In this section, we illustrate our proposed method using a real clinical study of a Cer-
agem massage (CGM) thermal therapy bed, a device for treating lumbar disc disease.
In total, there are 186 patients with p = 50 covariates. There are 30 continuous covari-
ates, such as age and baseline measurements of the patient’s current conditions, e.g.,
lower back pain and leg numbness, all measured on 0-10 scales. The outcome variable
yi, representing the measurements of the lower back pain after the treatment or control
experiment, was recorded to study the treatment effect.
In the original study, the patients were randomly assigned to the treatment or
control groups. The corresponding Mahalanobis distance was 57.67, which indicates
a moderate covariate imbalance. To compare, we repeatedly assigned these patients
to treatment groups using the proposed method, complete randomization, and reran-
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Figure 7: Comparison of the distributions of the Mahalanobis distance obtained using
the proposed method, complete randomization, and rerandomization. Note that reran-
domization is represented by the portion of the complete randomization distribution
that lies to the left of the vertical line (M = 20, 30, 40).
domization (M < a and a = 20, 30, 40). The corresponding Mahalanobis distances are
plotted in Figure 7. Note that, in the right panel of Figure 7, we replicated the data
four times to n = 744 (which attempts to mimic the large sample size settings).
As seen from the figure, the Mahalanobis distances of the proposed method on the
original data (n = 186) are consistently lower than those of complete randomization.
If we had n = 744 patients, the Mahalanobis distance of the proposed method further
decreases toward 0. Few allocations of complete randomization could achieve the same
level of balance as the proposed. Rerandomization produces the Mahalanobis distances
to the left of the vertical lines (M = 20, 30, 40), which are still not comparable with
the proposed.
For each randomization method, we further simulated the outcome variable ysimi
according to ysimi = µˆ1T
sim
i + µˆ2(1 − T simi ) + xTi βˆ + simi , where T simi is the simulated
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patient allocation, simi is sampled from the residuals of the regression fitted to the
original data. µˆ1, µˆ2, and βˆ are the corresponding estimated regression coefficients.
Using the simulated outcome variable, we obtained the average treatment effect
using τˆ . The performance comparison is summarized in Table 4. The proposed method
exhibits the best performance compared with other methods especially under large
sample size. It yields the largest PRIV and the lowest variance. For rerandomization,
a smaller threshold results in better performance; however, this comes at the cost of
a longer computational time and a lower acceptance probability. Note that the R2 for
the regression fitted to the original data is only 0.33, therefore, the maximum of PRIV
is 0.33. Because of the finite sample size, the optimal PRIV cannot be achieved. We
can see that if we increase the sample size, the PRIV of the proposed method is greatly
improved and is close to optimal, whereas that of the rerandomization method does
not improve at all. The gain from the proposed method is quite substantial.
6 Discussion
In this article, we have introduced a new randomization procedure for balancing the
covariates to improve the estimation accuracy for causal inference and clinical trials.
Compared with traditional methods, the proposed method can cope with a large num-
ber of covariates and a large sample size, which is especially advantageous in the era of
big data. The proposed method also shows superior performance in terms of computa-
tional time. In addition, it achieves optimality under the linear regression framework,
in the sense that, asymptotically, the proposed method can balance the covariates so
well that the imbalance adjustment provided by linear regression is not needed.
Although the proposed method is different from the minimization methods (Wei,
1978; Begg and Iglewicz, 1980; Smith, 1984a,b), it can be extended to such settings.
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Sample Size Method PRIV MSE (or Var) un or va
n = 186
Proposed 19.7% 0.081 0.502
RR (M < 40) 12.2% 0.090 0.730
RR (M < 30) 15.1% 0.085 0.562
RR (M < 20) 20.3% 0.081 0.501
CR - 0.100 -
n = 744
Proposed 27.4% 0.018 0.205
RR (M < 40) 10.9% 0.022 0.718
RR (M < 30) 14.6% 0.021 0.556
RR (M < 20) 20.6% 0.018 0.380
CR - 0.025 -
Table 4: Comparison of the proposed method with rerandomization and complete
randomization for real data analysis.
Instead of selecting a pair of units, we can select only one unit to allocate. However, the
behavior of the Mahalanobis distance in such a scenario will be further complicated,
because the proportion of the treatment group (i.e.,
∑n
i=1 Ti/n) then becomes a random
variable. We believe that the allocation procedure should be slightly modified such that
both the Mahalanobis distance and the proportion are controlled. In such a scenario,
we anticipate that the rate of convergence of the Mahalanobis distance can be further
improved. We leave this possibility as a topic for future investigation.
The proposed method is following the similar spirit of the minimization methods
used in clinical trials (Taves, 1974; Pocock and Simon, 1975; Hu and Hu, 2012). How-
ever, the focus and context of these methods are different from ours. Their methods are
applicable for patients sequentially enrolled in a clinical trial. On the other hand, our
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proposed method can be applied both in clinical trials where units enrolled sequentially,
and also in causal inference where all units are collected before the randomization and
experiment starts. Another significant difference is that the minimization methods are
suitable for discrete covariates, minimizing the margin and stratum imbalance. The
proposed method, in contrast, is suitable for both discrete and continuous covariates.
Throughout the article, we have focused on equal proportion allocation. However,
the proposed method can be easily extended to accommodate unequal proportions. For
example, to achieve a ratio of 1 : 2, in each iteration, we can allocate three units at a
time to maintain the targeted proportions.
Many other potential directions for further research remain as well. For example,
we have shown the optimality of the estimated treatment effect. An extension to
hypothesis testing is also of interest (Ma et al., 2015). The optimality of the estimator
hints at the most powerful test for the treatment effect. In addition, as the number of
covariates increases, it is more efficient to balance only the most important covariates
(Morgan and Rubin, 2015); therefore, the selection of the important covariates to
balance in our proposed framework is an interesting topic. The proposed method may
also be applied to balance important covariates in the field of crowdsourced-internet
experimentation.
7 APPENDIX
We provide outlines of the key proofs in the Appendix. The supplementary materials
contain detailed proofs of all theorems.
Proof of Theorem 2.1. We first convert the covariates to canonical form (Rubin and
Thomas, 1992). Let Σ = cov(x) and zi = Σ
−1/2xi where Σ−1/2 is the Cholesky square
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root of Σ−1. Suppose that n is even. By the assumption, cov(zi) = I, and
M∗(n) = npn(1− pn)(z¯1 − z¯2)T (z¯1 − z¯2).
We further define
yn =
n
2
(z¯1 − z¯2) =
∑
i:Ti=1
zi −
∑
i:Ti=0
zi,
∆n+2 = (−1)Tn+2(zn+1 − zn+2).
We can see that {yn,yn+2,yn+4...} is a Markov process and yn+2 = yn + ∆n+2. Define
the test function V (yn) = y
T
nyn. By denoting E[ · |yn] = En[ · ], we have
En[V (yn+2)]− V (yn) = En[yTn+2yn+2]− yTnyn = 2En[yTn∆n+2] + En[∆Tn+2∆n+2],
where En[∆Tn+2∆n+2] = En[(−1)2Tn+2(zn+1−zn+2)T (zn+1−zn+2)] is a positive constant.
For the first term on the right, we have
En[yTn∆n+2] = En[yTn (−1)Tn+2(zn+1 − zn+2)]
= En
{
E
[
yTn (−1)Tn+2(zn+1 − zn+2)
∣∣∣zn+1, zn+2]}
= En
{
(1− 2q)|yTn (zn+1 − zn+2)|
}
= En
{
(1− 2q)|yn| |zn+1 − zn+2| | cos θ|
}
= (1− 2q)|yn| En[|zn+1 − zn+2|] En[| cos θ|],
where θ is the angle between yn and zn+1 − zn+2. Note that En[|zn+1 − zn+2|] and
En[| cos θ|] are two positive constants. Since 1 − 2q < 0, there exist a constant b > 0
and c < 0, such as when |yn| > b, En[yTn∆n+2] + En[∆Tn+2∆n+2] < c. Therefore,
En[V (yn+2)] − V (yn) < c for |yn| > b. Similarly, we have En[V (yn+2)] − V (yn) <
En[∆Tn+2∆n+2] for |yn| ≤ b. By the “drift conditions” (Meyn and Tweedie, 2009), we
know yn has a stationary distribution. Therefore, nM
∗(n)/(4pn(1 − pn)) = yTnyn has
a stationary distribution and M∗(n) = Op(n−1).
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In practice, covariance materix Σ is not known and is sequentially estimated as Σ̂n.
We write the Mahalanobis distance as
M(n) =npn(1− pn)(x¯1 − x¯2)T Σ̂−1n (x¯1 − x¯2).
=npn(1− pn)(x¯1 − x¯2)T (Σ̂−1n + Σ−1 − Σ−1)(x¯1 − x¯2).
=M∗(n) + npn(1− pn)(x¯1 − x¯2)T (Σ̂−1n − Σ−1)(x¯1 − x¯2)
=M∗(n) + npn(1− pn)(x¯1 − x¯2)TΣ−1/2Σ1/2(Σ̂−1n − Σ−1)Σ1/2Σ−1/2(x¯1 − x¯2)
=M∗(n) + npn(1− pn)(z¯1 − z¯2)T (Σ1/2Σ̂−1n Σ1/2 − I)(z¯1 − z¯2)
Note that (z¯1− z¯2)T (Σ1/2Σ̂−1n Σ1/2−I)(z¯1− z¯2) can be considered as the weighted norm
of z¯1 − z¯2, i.e., ||z¯1 − z¯2||W where W = Σ1/2Σ̂−1n Σ1/2 − I = Σ1/2(Σ̂−1n − Σ)Σ1/2. Since
Σ̂n
p→ Σ, we have M(n) = Op(M(n))
Proof of Theorem 3.3. We first convert the covariates to canonical form (Rubin and
Thomas, 1992). Let Σ = cov(x) and zi = Σ
−1/2xi where Σ−1/2 is the Cholesky square
root of Σ−1. Suppose n is even. By the assumption of normality, zi ∼ N(0, I).
Define
Y =

y1
y2
...
yn

,Z =

zT1
zT2
...
zTn

,T =

T1
T2
...
Tn

, T˜ =

T1 1− T1
T2 1− T2
...
...
Tn 1− Tn

,
and Z˜ = [T˜ ;Z], γ = (γ1, ..., γp)
T = (Σ−1/2)Tβ, µ = (µ1, µ2)T and γ∗ = (µT ,γT )T =
(µ1, µ2, γ1, ..., γp)
T .
Then true model, equation (2), can be rewritten as
Y = X˜β∗ +  = T˜ µ+Xβ +  = T˜ µ+Zγ +  = Z˜γ∗ + .
Part I: τˆPSR
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Suppose K = (1,−1), then τˆPSR can be obtained by running the regression, Y =
T˜ µ + , even though the true model is Y = Z˜γ∗ +  = T˜ µ +Zγ + . In particular,
we can write τˆPSR as
τˆPSR =
∑n
i=1 Tiyi∑n
i=1 Ti
−
∑n
i=1(1− Ti)yi∑n
i=1(1− Ti)
= K
(
T˜ T T˜
n
)−1
T˜ TY
n
= K
(
T˜ T T˜
n
)−1
T˜ T (Z˜γ∗ + )
n
= K
(
T˜ T T˜
n
)−1
T˜ T (T˜ µ+Zγ + )
n
= K
[
µ+
(
T˜ T T˜
n
)−1
T˜ T (Zγ + )
n
]
= µ1 − µ2 +K
(
T˜ T T˜
n
)−1
T˜ T (Zγ + )
n
.
We know, as n→∞,
T˜ T T˜
n
p→
0.5 0
0 0.5
 = M .
We further define
A = KM−1
[
T˜ T (Zγ + )
n
]
,
B = K
[( T˜ T T˜
n
)−1
−M−1
][
T˜ T (Zγ + )
n
]
,
so that τˆPSR = A+B.
For A, with some algebra, we can show
A =
2
n
[ p∑
j=1
n∑
i=1
(2Ti − 1)γjzi,j +
n∑
i=1
(2Ti − 1)i
]
.
For the first term on the right, we have
p∑
j=1
n∑
i=1
(2Ti − 1)γjzi,j =
p∑
j=1
γj
[ ∑
i∈{i:Ti=1}
zi,j −
∑
i∈{i:Ti=0}
zi,j
]
.
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where {i : Ti = 1} and {i : Ti = 0} represent the two treatment groups. From
the proof of Theorem 2.1, we understand that
∑
i∈{i:Ti=1} zi,j −
∑
i∈{i:Ti=0} zi,j is a
stationary process under the proposed method (i.e. a mean reverting process as n →
∞). Therefore,
∑
i∈{i:Ti=1}
zi,j −
∑
i∈{i:Ti=0}
zi,j = Op(1),
p∑
j=1
γj[
∑
i∈{i:Ti=1}
zi,j −
∑
i∈{i:Ti=0}
zi,j] = Op(1).
In addition, note that (2Ti − 1)2 = 1, we have
Var
(
2
n
n∑
i=1
(2Ti − 1)i
)
= E
(
4
n2
n∑
i=1
(2Ti − 1)22i
)
= E
(
4
n2
n∑
i=1
2i
)
=
4σ2
n
.
Therefore,
√
nA
D→ N(0, 4σ2 ).
Similarly, for B, we will show
√
nB
p→ 0. First note that
( T˜ T T˜
n
)−1
−M−1 p→ 0.
Therefore, showing
√
nB
p→ 0 is equivalent to show
T˜ T (Zγ + )√
n
= Op(1).
First, notice that
T˜ T (Zγ + )√
n
=
1√
n
 ∑pj=1∑ni=1 Tiγjzi,j +∑ni=1 Tii∑p
j=1
∑n
i=1(1− Ti)γjzi,j +
∑n
i=1(1− Ti)i
 .
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Since
1√
n
( p∑
j=1
n∑
i=1
Tiγjzi,j +
n∑
i=1
Tii
)
=
1
2
[
1√
n
( p∑
j=1
n∑
i=1
γjzi,j +
n∑
i=1
i
)
+
1√
n
( p∑
j=1
n∑
i=1
(2Ti − 1)γjzi,j +
n∑
i=1
(2Ti − 1)i
)]
.
By central limit theorem, we have
1√
n
( p∑
j=1
n∑
i=1
γjzi,j +
n∑
i=1
i
)
= Op(1).
In addition,
1√
n
( p∑
j=1
n∑
i=1
(2Ti − 1)γjzi,j +
n∑
i=1
(2Ti − 1)i
)
=
√
nA
2
.
Since
√
nA converges to a normal distribution,
1√
n
( p∑
j=1
n∑
i=1
(2Ti − 1)γjzi,j +
n∑
i=1
(2Ti − 1)i
)
= Op(1).
Therefore,
1√
n
( p∑
j=1
n∑
i=1
Tiγjzi,j +
n∑
i=1
Tii
)
= Op(1).
By symmetry, we have
1√
n
( p∑
j=1
n∑
i=1
(1− Ti)γjzi,j +
n∑
i=1
(1− Ti)i
)
= Op(1).
Therefore,
T˜ T (Zγ + )√
n
= Op(1).
Hence,
√
nB
p→ 0, together with √nA D→ N(0, 4σ2 ), by Slutsky’s theorem, we have
√
n(τˆPSR − (µ1 − µ2)) D→ N(0, 4σ2 ).
For τˆCR, τ˜PSR, and τ˜CR, we can obtain their asymptotic distributions in similar
ways. Please see supplementary materials for details.
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